Amivantamab domestic launch date

Amivantamab (Amivantamab) is a new targeted antibody drug used to treat certain patients with non-small cell lung cancer (NSCLC). It is designed to fight EGFR (epidermal growth factor receptor) mutant NSCLC, a subtype of lung cancer. EGFR-mutant NSCLC is often resistant to traditional treatments, but evantumumab provides a new treatment option for this patient group. As a targeted antibody drug, evantumumab is usually given to patients via intravenous injection. Evantumumab The original drug was approved for medical use in the United States in May 2021 and in the European Union in December 2021. It has not yet been launched in China, and the specific time for launch is unclear.